Patent Grant
8088918
The present invention relates to novel noncardiotoxic compounds and pharmaceutical compositions useful in the treatment of a variety of disorders including the treatment of depression, allergies, psychoses, infection, cancer and gastrointestinal disorders. The compounds and pharmaceutical compositions of the present invention are useful in the prevention and/or reduction of severe cardiac conductance and cardiac rhythm disturbances and the cardiac arrhythmias such as torsade de pointes that lead to sudden cardiac death.
The annual incidence of sudden cardiac death is estimated to be greater than 400,000 persons in the United States alone, and accounts for approximately 50% of all deaths from cardiovascular disease (Chugh et al. Journal American College of Cardiology 44: 1268-1275 (2004); U.S. Centers for Disease Control; Chugh et al. Circulation 102:649-654 (2000)). Although the occurrence of sudden cardiac death in the general population is high, the incidence (as a percent of the total) in patients over 64 years of age and in patients with cardiovascular disease is considerably higher (Huikuri et al. New England Journal of Medicine 345(2):1473-1482 (2001); Morbidity and Mortality: 2004 Chart Book on Cardiovascular, Lung and Blood Diseases, National Institutes of Health (May 2004); and Myerburg et al. Annals of Internal Medicine 119:1187-1197 (1993)). According to the World Health Organization, the non-cardiovascular drugs most commonly associated with torsade de pointes between 1983 and 1999 are gastrointestinal, antiinfective, antidepressant, antihistaminic and antipsychotic agents. Moreover, antipsychotic, antidepressant and cardiovascular drugs account for over 40% of fatalities for all pharmaceutical agents (The 2002 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System (AAPCC-TESS)).
It has been reported that the incidence of sudden cardiac death is clearly associated with increasing amounts of antidepressant and antipsychotic drugs at therapeutically relevant doses (Ray, A R et al. Clinical Pharmacology and Therapeutics 75(3): 234-241 (2004); Ray, A R et al. Archives General Psychiatry 58: 1162-1167 (2001)). Although low therapeutic doses of these types of drugs (<100 mg daily) are not associated with sudden cardiac death, moderate and high therapeutic doses of these drugs (≧100 mg daily) are clearly associated with sudden cardiac death. Not only is the incidence of sudden death in patients with cardiovascular disease and treated with these drugs considerably higher than patients without cardiovascular disease, the incidence of sudden death in these patients is clearly correlated with the severity of cardiovascular disease (Ray, A R et al. Archives General Psychiatry 58: 1162-1167 (2001)).
Antipsychotics primarily antagonize central dopaminergic D2 receptor neurotransmission, although they also have antagonist effects at muscarinic, serotonergic, α1-adrenergic, and H1-histaminergic receptors. Because antipsychotics are also are used as sedatives, as antiemetics, to control hiccups, to treat migraine headaches, and as antidotes for drug-induced psychosis, the adverse effects of antipsychotics are not confined to psychiatric patients. Antipsychotics are capable of causing orthostatic and severe hypotension, as well as prolongation of the QTc interval and QRS which can result in arrhythmias. Antipsychotics account for about 18 % of moderate (pronounced) toxicity, over 20% of life-threatening toxicity and 17% of the fatalities of all pharmaceuticals.
Tricyclic antidepressants cause the overwhelming majority of antidepressant poisoning in the United States resulting in morbidity and mortality; the most severe toxicity occurs in the cardiovascular system. Antidepressants account for about 15 % of moderate (pronounced) toxicity and 18% of life-threatening toxicity of the fatalities of all pharmaceuticals.
Antidepressants affect the prolongation of the QTc interval causing cardiotoxicity that result from direct myocardial depression, cardiac conduction disturbances, effects on peripheral vasomotor tone, and changes in the autonomic nervous system. The interactions of tricyclic antidepressants with fast sodium channels in cardiac tissue results in slowed cardiac conduction (e.g. prolonged QRS on the ECG), impaired cardiac contractility and possible ventricular dysrhythmias and inhibition of repolarization in His-Purkinje myocytes (e.g. prolonged QTc on the ECG).
Torsade de pointes is a particular cardiac problem associated with many therapeutic agents and has been implicated as a possible cause of sudden death, particularly in those individuals with a past history of disturbances of cardiac rhythm, myocardial infarction, congenital repolarization abnormalities and cardiac risk factors such as hyperlipidemia and age. This arrhythmia is a variant of paroxysmal ventricular tachycardia associated with a prolonged QTc interval or prominent U waves on the ECG. Although torsade de pointes might remit spontaneously, it is potentially lethal because it can progress to ventricular fibrillation, life-threatening arrhythmias or precipitate sudden death.
Drug-induced QTc interval prolongation may be clinically important even if the mean increase is not very large. For example, the drug terodiline was withdrawn after causing QTc interval prolongation, torsade de pointes, and sudden death. In healthy volunteers, therapeutic plasma concentrations of terodiline are associated with increases in mean QTc of only 23 ms, which are similar to the increases associated with quinidine and prenylamine. Nevertheless, much larger increases occurred in a minority of patients who developed arrhythmias. These included those predisposed by existing problems such as heart disease and congenital repolarization abnormalities. Thus, benign QTc interval prolongation in one subject may indicate that another more susceptible patient might develop extreme QTc interval prolongation and arrhythmias with the same drug at the same dose. Furthermore, small increases in QTc interval might increase the risk of ventricular fibrillation/torsade de pointes over a large population. The number of excess cases of sudden death in the large numbers of patients with minor QTc interval prolongation might actually exceed those in the small numbers of patients with extreme QTc interval prolongation. Nevertheless, the potential of a drug to cause QTc interval prolongation is currently believed to be the lower threshold of determining the cardiotoxicity of a therapeutic drug.
To date, the understanding of QTc interval prolongation has focused on defective repolarization of the heart through blockade of K+ channels, either alone or in combination with Na+ channel modulation. Prevailing theories also suggest that the arrhythmogenic potential of drugs is based on elevated plasma levels of parent drug that are not metabolized. Despite attempts to correlate the blockade of human cardiac K+ channels, such as the Herg channel, with torsade de pointes and sudden cardiac death, very little evidence exists to support this correlation. In fact, a number of severely cardiotoxic drugs that have been withdrawn from the market or denied approval by the FDA have insignificant effects on the Herg channel.
Although data has existed for decades that demonstrates adverse conductance changes and arrhythmias in patients having higher than normal plasma concentrations of drug metabolites, the cardiotoxic effects of these metabolites have received relatively little attention. These observed adverse cardiac conductance changes reflect significant changes in cardiac depolarization (QRS interval prolongation and dispersion) and atrial block (PR interval prolongation) that were correlated with elevated plasma levels of hydroxylated drug metabolites in clinical studies (Kutcher S P et al. British Journal of Psychiatry 148: 676-679 (1986); Stern S L et al. Journal of Clinical Pharmacology 11: 93-98 (1991); Vozeh S et al. American Journal of Cardiology 59: 681-684 (1987); Vozeh S et al. Clinical Pharmacology and Therapeutics 37:575-581 (1985); Drayer D E et al. Clinical Pharmacology and Therapeutics 24: 31-39 (1978)); in isolated perfused heart studies (Uematsu T et al. Archives of International Pharmacodynamics 297: 29-38 (1989); Uematsu T. et al. Journal of Pharmacological Methods 18: 179-185 (1987); and in animal studies (Pollock B G Ph.D. Dissertation University of Pittsburgh 1987; Pollack B G and Perel J M Psychopharmacology 109: 57-62 (1992); Jandhyala H S et al. European Journal of Pharmacology 42: 403-410 (1977)). Hydroxylated drug metabolites have also been reported to be responsible for severe cardiotoxic effects in vitro (Chem. Res. Toxicology (17: 623-632 (2004)).
A considerable number of cardiovascular and noncardiovascular therapeutic agents rely on secondary and tertiary amine structural motifs in their chemical structure that are responsible for their pharmacological activity. Many cardiovascular drugs, including antiarrhythmics, calcium channel antagonists, adrenergics and P-blockers contain essential secondary and tertiary amines in their chemical structure. Entire therapeutic classes of non-cardiovascular drugs, including antidepressants, antihistamines and antipsychotics rely on the secondary and tertiary amine functionality for their primary activity. Others, such as gastrointestinal and antiinfective drugs do not necessarily rely on the secondary and tertiary amine group for their primary activity; but, include this structural motif as part of their chemical structure. Cardiotoxicity associated with the therapeutic use of secondary and tertiary amine-containing drugs is reflected in a variety of cardiac disturbances, including notable changes in ECG, polymorphic ventricular tachycardia, negative inotropism, drops in blood pressure, orthostatic hypotension and depressed cardiac contractility resulting in acute cardiac arrest.
Serious cardiac arrhythmias (both fatal and non-fatal) including tachycardia, ventricular fibrillation, torsade de pointes, and QTc interval prolongation have been reported in patients taking individual secondary and tertiary amine-containing drugs that are oxidized by cytochrome P450 2D6 or combinations of secondary and tertiary amine-containing drugs that inhibit cytochrome P450 3A4. Drugs known to inhibit metabolism of secondary and tertiary amine-containing drugs by cytochrome P450 3A4 include, inter alia, ketoconazole, itraconazole, micoconazole, troleandomycin, erythromycin, fluconazole and clarithromycin. It is generally believed that inhibition of a drug's metabolism by cytochrome P450 3A4 increases the plasma concentration of the parent amine-containing drug to toxic levels; however, this view has not been supported by rigorous examination and discrimination between plasma levels of the parent drugs and their metabolites. An alternate explanation is that inhibition of cytochrome P450 3A4 by inhibitors administered concomitantly “switches” the metabolism of the parent compound from one involving both cytochrome P450 3A4 and cytochrome P450 2D6 to the metabolism of the parent drug primarily by cytochrome P450 2D6.
Cisapride (Propulsid®), shown below, was commonly used to treat nocturnal heartburn as well as a variety of other gastrointestinal disorders:
Cisapride (Propulsid®) was recently removed from the market by the FDA because of the QTc interval prolongation and life-threatening ventricular arrhythmias such as torsade de pointes which produced sudden cardiac death. These cardiotoxic effects are believed to be due to cardiac conduction delays such as the specific and potent blockade of human cardiac K+ channels, particularly the HERG channels. The specific, high affinity block of the human cardiac K+ channel HERG by cisapride (IC50 of 0.045 μM) is similar to that observed for the class III antiarrhythmic agent dofetilide (IC50 of 0.010 μM) and the nonsedating antihistamines astemizole (IC50) of 0.001 μM) and terfenadine (IC50) of 0.213 μM). It is further believed that this blockade of human cardiac K+ channels underlies the proarrhythmic effects of the drug observed under certain clinical settings. In guinea pig ventricular myocytes cisapride elicited a concentration-dependent block (IC50 of 46.9 μM) of L-type Ca2+ channels suggesting that the inhibitory effect of cisapride on calcium channels might also contribute to its cardiotoxicity under pathophysiological conditions. Cisapride is metabolized by both cytochrome P450 3A4 and cytochrome P450 2D6; however the primary metabolic route is believed to be through cytochrome P450 3A4. When higher than normal dosages of cisapride are used or with concomitant ingestion of imidazole antifungals or macrolide antibiotics, it is believed that cisapride is metabolized to cardiotoxic metabolites through aromatic hydroxylation primarily by cytochrome P450 2D6.
Astemizole (Hismanal®) and terfenadine (Seldane®) are H1 histamine antagonists that have also been removed from the market by the FDA because of QTc interval prolongation and ventricular arrhythmias such as torsade de pointes which produced sudden cardiac death.
Astemizole (Hismanal®), shown below, was commonly used to treat the symptoms associated with seasonal allergic rhinitis and chronic idiopathic urticaria.
Terfenadine (Seldane®), shown below, was commonly used to symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation.
Astemizole (Hismanal®) and terfenadine (Seldane®) are metabolized by both cytochrome P450 3A4 and cytochrome P450 2D6, and at least astemizole is believed to be metabolized to cardiotoxic metabolites through aromatic hydroxylation. Terfenadine is believed to be metabolized to cardiotoxic metabolites primarily through aliphatic oxidation. Terfenadine and astemizole suppress the HERG current with IC50 of 0.213 μM and 0.001 μM, respectively. Clinical use of astemizole and terfenadine has been associated with hypotension, QTc interval prolongation, development of early after-depolarization, torsade de pointes, cardiac arrest and sudden death. It is believed that torsade de pointes occurs when higher than normal dosages of astemizole are used or with concomitant ingestion of imidazole antifungals or macrolide antibiotics. Concomitant administration of astemizole with ketoconazole, itraconazole, erythromycin, clarithromycin or quinine was contraindicated. It is believed that these cardiovascular effects resulting in electrocardiographic conductance defects are associated with elevation of astemizole or its metabolites in plasma. Norastemizole is 13- to 16-fold more potent as an H1 antagonist than astemizole and 20- to 40-fold more potent in inhibiting histamine-induced bronchoconstriction.
Sertindole, shown below, was an atypical antipsychotic agent commonly used for the treatment of schizophrenia outside of the United States:
In 1996, sertindole (Serlect®) was rejected by the Food and Drug Administration because it prolonged the QTc interval and was associated with a significant number of unexplained deaths in clinical trials. Sertindole had been approved in 19 European countries, but more evidence of associated arrhythmias led to its withdrawal in Europe.
In trials involving more than 2,000 patients up to June 27, 1996 patients died while receiving sertindole, including 13 sudden deaths. Although there was no proof that the drug actually caused these deaths, sertindole was known to induce QT interval prolongation in some patients. Other antipsychotics have been associated with QT interval prolongation, and sudden death has been associated with schizophrenia.
Secondary and tertiary amines and other drug substrates for the P450 2D6 isozymes are lipophilic compounds that posses a planar component and are strong organic bases that are protonated at physiological pH. It is believed that a charged nitrogen atom on these amines is required to orient the drug correctly within the P450 2D6 active site where metabolic oxidation occurs. At this site, it is believed that the secondary or tertiary amine molecule adopts a conformation in which the positively-charged nitrogen (N+) atom is oriented towards an anionic location (COO−) on the P450 2D6 protein while the aromatic ring is aligned with a relatively planar, hydrophobic region of the protein. It is believed that when this conformation is adopted the nitrogen atom and the metabolic oxidation are in close proximity and metabolism of the drug occurs. Although cytochrome P450 3A4 is located both in the liver and the intestine, P450 2D6 is located in the liver and not the intestine.
Metabolic oxidation of drugs and other xenobiotic substances is a first step in a biotransformation that the body relies on to distribute active drug metabolites to tissues and also to eliminate them from the body. In some cases, this metabolic oxidation involves the formation of a pharmacologically active metabolite, and in other cases it involves the formation of hydroxylated metabolites through oxidation of an aromatic ring. Although metabolic oxidation to pharmacologically active metabolites is essential, metabolism of secondary and tertiary amine-containing drugs to hydroxymetabolites by cytochrome P450 2D6 and cytochrome P450 3A4 has serious cardiotoxicity implications to patients, particularly at high oral doses. We have found that the hydroxymetabolites are primarily responsible for the cardiotoxicity and not the parent secondary and tertiary amine-containing drugs. Published studies in humans (Dencker H et al. Clinical Pharmacology and Therapeutics 19: 584-586 (1976)) have also shown that the concentration of the tertiary-amine drugs is highest after leaving the liver and immediately prior to reaching the heart (8-10 times the concentration in the systemic circulation). Consequently, a patient is at highest risk during the first-pass metabolism of the secondary and tertiary amine drugs when the concentration of the cardiotoxic hydroxymetabolites is highest.
Published studies in humans (Gram L F and Christiansen J Clinical Pharmacology and Therapeutics 17: 555-563 (1975) have further shown that the concentration of the hydroxymetabolites of imipramine in plasma reaches significantly higher levels that the parent compounds or their active metabolites.
Likewise, published studies (Segura M et al. Rapid Communications in Mass Spectrometry 17: 1455-1461 (2003)) report that the concentration of the hydroxymetabolites of paroxetine in human plasma reaches significantly higher levels that the parent compounds or their active metabolites.
Consequently, a patient is at greatest risk during the first-pass metabolism of the secondary and tertiary amine drugs when the concentration of the cardiotoxic hydroxymetabolites is highest. We believe that reventing metabolism of secondary and tertiary amine-containing drugs to hydroxymetabolites by cytochrome P450 2D6 and cytochrome P450 3A4 important to reducing their cardiotoxicity.
Inhibition studies on a series of imipramine analogs were conducted and the analogs tested for CYP2D6 activity, the enzyme that is responsible for the formation of the cardiotoxic hydroxylated metabolites (Halliday R C et al. European Journal of Drug Metabolism and Pharmacokinetics 22: 291-294 (1997)). The analogs of imipramine that were tested were designed to have the positively charged nitrogen atom removed from the active site of CYP2D6. The three approaches were adjustment of alkyl chain length, alkyl bond rigidity (restricted bond rotation) and removing the positive charge on the tertiary nitrogen atom using the prodrug imipramine-N-oxide. Halliday et al. reported that removal of the positively charged nitrogen atom of imipramine from the active site of CYP2D6 either by lengthening the alkyl chain length or altering the pKa of imipramine with using imipramine-N-oxide abolished the metabolism of imipramine by CYP2D6 to the hydroxymetabolite.
A considerable amount of preclinical and clinical data is available that demonstrates that imipramine-N-oxide is not subject to first-pass metabolism or aromatic hydroxylation to the cardiotoxic hydroxymetabolites by cytochrome P450 2D6 and cytochrome P450 3A4. This prodrug is rapidly converted in the systemic circulation to imipramine which is then metabolized under much lower systemic plasma concentrations to the active form (desipramine) and hydroxylated metabolites that are not as likely to produce severe cardiotoxicity. In published preclinical and clinical studies imipramine-N-oxide has been shown not produce the cardiotoxicity of the tertiary amine drug imipramine. Nevertheless, formulation difficulties and the complexities of imipramine-N-oxide metabolism in plasma limits its use.
It is believed, in accordance with the present invention that the piperidine chemical group with its tertiary amine in cisapride, astemizole, sertindole, trazadone, nefazadone, buspirone and terfenadine contributes to cardiac conduction disturbances and orientation of the drugs within the binding sites of the cytochrome enzymes responsible for the responsible metabolism of these drugs by aromatic or cycloalkyl hydroxylation.
It is further believed that the chemically related piperazine chemical group with its tertiary amine contributes to cardiac conduction disturbances and orientation of the drugs within the binding sites of the cytochrome enzymes responsible for the responsible metabolism of these drugs by for aromatic or cycloalkyl hydroxylation. Pharmacologic agents containing a piperazine group known to cause cardiac conduction disturbances include buclizine, buspirone, cyclizine, doxazosin, fluphenazine, gepirone, hydroxyzine, itraconazole, ketoconazole, loxapine, meclizine, olanzapine, perphenazine, quetiapine, trazadone, nefazadone and ziprasidone. By way of example, the chemical structures of a series of pharmacological compounds containing a piperazine moiety and having antihistamine activity are shown below:
Fluoroquinolone antibiotics are pharmacologic agents containing a piperazine group known to cause serious cardiac conduction disturbances and torsade de pointes. Fluoroquinolone antibiotics approved for marketing and having a secondary amine on the piperazine ring include norfloxacin, lomefloxacin, ciprofloxacin, enoxacin, gatifloxacin, sparfloxacin, temafloxacin, grepafloxacin and moxifloxacin. Several of these fluoroquinolone agents have already been removed from the market because of life-threatening cardiac conduction disturbance or torsade de pointes. By way of example, the chemical structures of a series of fluoroquinolone compounds containing a secondary amine on the piperazine moiety are shown below:
Fluoroquinolone antibiotics approved for marketing and having a secondary amine on the piperidine ring include moxifloxacin as shown below:
It is therefore an object of the present invention to provide non-cardiotoxic pharmacologically active compounds having modulated cytochrome P 450 metabolism.
It is a further object of the invention to provide non-cardiotoxic pharmacologically active compounds having reduced metabolism by cytochrome P450 2D6.
It is a further object of the invention is to provide non-cardiotoxic prodrugs of pharmacologically active compounds having modulated cytochrome P 450 metabolism.
It is a further object of the invention to provide non-cardiotoxic pharmacologically active compounds having reduced metabolism by cytochrome P450 2D6 and cytochrome P450 3A4.
A further object of the invention is to provide non-cardiotoxic prodrugs that will modify the physicochemical properties of tertiary amine-containing drugs such that these drugs will exhibit reduced binding to the CYP2D6 metabolizing enzymes during first-pass absorption.
A further object of the invention is to provide non-cardiotoxic prodrugs that can be hydrolyzed in the plasma after absorption and be converted directly to the therapeutically active form of the parent compounds.
A further object of the invention is to provide non-cardiotoxic prodrugs that lower the pKa of the tertiary amine group to a level such that the majority of the tertiary amine is uncharged at physiological pH (pH 7.4). For example, imipramine has pKa of 9.5 and is completely ionized as it is transported through the gastrointestinal tract. After oral ingestion, imipramine is rapidly and completely absorbed from the small intestine, with peak plasma concentration within two to five hours. Imipramine is subject to extensive first-pass metabolism in the liver, and is eliminated by demethylation to the active metabolite, desipramine and to a lesser extent by aromatic hydroxylation to 2-hydroxyipramine. Desipramine, in turn, is metabolized by aromatic hydroxylation to 2-hydroxydesipramine. The systemic availability of imipramine in healthy subjects ranges from 27% to 80% and the corresponding first-pass metabolism ranges from 20% to 73%. Imipramine-N-oxide, a nitrogen-atom prodrug of imipramine which has a pKa of about 4.7, has a systemic availability of about 100% after oral administration suggesting that there is no first pass effect. Both preclinical and clinical studies have shown that the cardiotoxicity of imipramine-N-oxide is significantly reduced over that of imipramine.
In accordance with the present invention, disclosed are enzyme-labile compounds having the formula
where R1 and R2 are independently hydrogen, alkyl having from 1 to about 7 carbon atoms, aryl, aralkyl, and cycloalkyl having from about 3 to about 6 carbon atoms, Y is (CH2)n where n is from 0 to 2, Z is alkyl, alkoxy, alkoxy, aryloxy, or alkylaryloxy where m is from 0 to about 4, and R3 is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylaryloxy, substituted or unsubstituted indole, substituted or unsubstituted phenothiazine, substituted or unsubstituted dibenzoxazepine, substituted or unsubstituted dibenzathiazepine, substituted or unsubstituted oxopthalazine, substituted or unsubstituted quinoline, substituted or unsubstituted dihydroquinoline, substituted or unsubstituted dibenzodiazepine, substituted or unsubstituted benzocycloheptapyridine, substituted or unsubstituted carbazol, substituted or unsubstituted tetrahydrocarbazols, substituted or unsubstituted dibenzocycloheptenes, substituted or unsubstituted benzoimidazoles, substituted or unsubstituted piperazines, substituted or unsubstituted benzamides, substituted or unsubstituted benzhydrol, and substituted or unsubstituted diazabenzoazulene, substituted or unsubstituted oxobenzimidazole, 3,4 pyrrolo-dihydroquinoline, carbamoyl-2,3,4,9-tetrahydro-cabazol, and pharmaceutically acceptable salts thereof.
These enzyme-labile compounds, having lower pKa values than their corresponding secondary and tertiary amines, have significantly reduced cardiotoxicity than those secondary and tertiary amines from which they are derived. The compounds of the present invention are useful as gastrointestinal, antiinfective, antidepressant, antihistaminic, antipsychotic, antineoplastic and cardiovascular therapeutic agents.
In accordance with the present invention, disclosed are enzyme-labile prodrugs having a modified ionization potential (pKa) of the nitrogen atoms such that they are significantly less basic than on the highly basic nitrogen atoms of the parent drugs. In accordance with the present invention we describe chemical modifications of the highly basic that amines include formation of phosphoramidates which are stable toward hydrolysis in the intestine and plasma. Phosphoramidates are non-toxic organophosphorous compounds containing phosphorous-nitrogen bonds.
An unexpected advantage of these organophosphorous compounds over the N-oxides is that they are enzyme-labile and are selectively hydrolyzed after passage through the intestine to the pharmacologically active drug moiety. Unlike other prodrug technologies employing esters, phosphonates and peptide bonds, which are hydrolyzed by esterases, phosphatases and peptidases in the intestine, enterocytes, hepatic cells and plasma, the organophosphorous compounds of the present invention are stable in the intestine and the enterocytes and plasma.
In agreement with a limited number of published studies, we have shown that the hydroxymetabolites of several secondary and tertiary amine-containing drugs are primarily responsible for the cardiotoxicity and not the parent compound. In Langendorff isolated perfused rabbit heart studies we have demonstrated that the hydroxymetabolites demonstrated dose-dependent significant increases in cardiac conductance, notably in PR interval prolongation, QRS interval prolongation and QT interval prolongation at clinically relevant doses. None of these changes were accompanied by observed conductance changes associated with K+ channel blockade. In receptor binding studies, no differences were noted in the affinity of the hydroxymetabolites and the parent drugs toward the voltage operated L-type calcium channel receptors or the Herg receptors of the K+ channel.
In accordance with the present invention, we describe enzyme-labile prodrugs of the secondary and tertiary amine moiety that mask the enzyme(s) primarily responsible for the production of these hydroxymetabolites in the liver. We describe enzyme-labile prodrugs of secondary and tertiary amine-containing drugs that are not substrates of cytochrome P450 CYP2D6. We describe enzyme-labile prodrugs of secondary and tertiary amine-containing drugs having minimal capacity for aromatic hydroxylation or first-pass metabolism to the cardiotoxic hydroxymetabolites. These enzyme-label prodrugs are expected to be rapidly converted in the systemic circulation to the pharmacologically active form of the secondary and tertiary amine-containing drugs which are then metabolized under much lower systemic plasma concentrations that are not as likely to produce severe cardiotoxicity.
These enzyme-labile prodrugs modulate the physicochemical properties of secondary and tertiary amine-containing drugs such that these drugs do not bind to the cytochrome P450 2D6 metabolizing enzymes during first-pass absorption at physiological pH. The nitrogen atoms on these enzyme-labile prodrugs are significantly less basic (pKa<5.4) than on the highly basic nitrogen atoms of the parent drugs (pKa˜9.5). Because these prodrugs are enzyme-labile, they can be hydrolyzed in the body after absorption directly to the non-cardiotoxic therapeutically active compounds. It is anticipated that specific therapeutic areas covered by this technology include, among others, all types of antidepressants, antihistamines, antipsychotics, gastrointestinal and several classes of antiinfective drugs. In a preferred embodiment of the present invention, chemical modification of the highly basic amines of known cardiotoxic drugs includes formation of phosphoramidates whose hydrolysis is primarily restricted to the liver and are stable in the intestine and plasma. Phosphoramidates are organophosphorous compounds containing phosphorous-nitrogen bonds.
A partial list of therapeutic compounds having a highly basic nitrogen atom that have reported cases of QT interval prolongation, torsade de pointes or both and their corresponding pKa values include the following: dextromethorphan (9.20), methadone (8.25), propoxyphene (8.91), tramadol (9.41), amoxapine (7.60), citalopram (9.50), clomipramine (9.50), desipramine (10.40), doxepin (8.00), duloxetine (10.00), escitalopram (9.60), femoxetine (9.00), fluoxetine (8.70), maprotiline (10.20), mianserin (8.26), mirtazapine (8.10), nefazodone (7.90), nortriptyline (10.10), paroxetine (9.90), selegiline (7.53), sertraline (9.50), venlafaxine (9.40), zimeldine (8.00), astemizole (9.90), azelastine (9.06), chlorpheniramine (9.20), chlorphenoxamine (8.21), clemastine (10.23), desloratadine (9.40), diphenhydramine (9.00), doxylamine (9.30), fexofenadine (9.53), promethazine (9.10), terfenadine (9.60), ciprofloxacin (7.68), halofantrine (9.60), levofloxacin(7.09), moxifloxacin (10.01), ofloxacin (7.09), rimantadine (11.70), tamoxifen (8.85), chlorpromazine (9.30), clozapine (8.20), loxapine (7.64), norsertindole (10.61), olanzapine (6.37), risperidone (8.24), sertindole (9.06), thioridazine (9.50), trifluoperazine (7.98), ziprasidone (8.24), amphetamine (9.90), atomoxetine (10.12), carbamazepine (7.00), cyclobenzaprine (9.21), fenfluramine (9.92), methamphetamine (10.28), methylphenidate (8.90), oxybutynin (6.96), phenytoin (8.31), sibutramine (9.36), tolterodine (9.87), cimetidine (6.80), cisapride (7.04), cyclizine (8.35), meclizine (7.32), norcisapride (8.46), ranitidine (8.20), almotriptan (9.58), eletriptan (10.13), frovatriptan (10.63), naratriptan (9.74), rizatriptan (9.49), rumatriptan (9.50), and Zolmitriptan (9.52).
In accordance with a preferred embodiment of the present invention, the pharmaceutical formulations comprise phosphoramidate-based prodrugs having pKa of less than about 5.4. In accordance with a more preferred embodiment of the present invention, the pharmaceutical formulations comprise phosphoramidate-based prodrugs having pKa values in the range from about 1 to about 5. In yet an even more preferred embodiment of the present invention, the phosphoramidate-based prodrugs have a pKa less than 4. It will be appreciated by those skilled in the art that this reduction in pKa represents a considerable difference in the proportion of positively charged amines present at physiological pH compared to the highly basic amine parent drugs.
Pharmaceutical compounds in accordance with the present invention have considerable similarity because of the similar pharmacologic requirements for therapeutic activity. Accordingly, the chemical structures of the enzyme-labile prodrugs can be characterized by a few general structure types. The first type include those containing cyclic aliphatic groups such as piperidine and piperazine containing a secondary or tertiary nitrogen atom such as found in amoxapine, and another type includes those having and alkylamine group such as found in imipramine.
In accordance with one embodiment of the present invention, compounds have the formula
where R1 and R2 are independently hydrogen, alkyl having from 1 to about 7 carbon atoms, aryl, aralkyl, and cycloalkyl having from about 3 to about 6 carbon atoms, Y is (CH2)n where n is from 0 to 2, Z is alkyl, alkoxy, alkoxy, aryloxy, or alkylaryloxy where m is from 0 to about 4, and R3 is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylaryloxy, substituted or unsubstituted indole, substituted or unsubstituted phenothiazine, substituted or unsubstituted dibenzoxazepine, substituted or unsubstituted dibenzathiazepine, substituted or unsubstituted oxopthalazine, substituted or unsubstituted quinoline, substituted or unsubstituted dihydroquinoline, substituted or unsubstituted dibenzodiazepine, substituted or unsubstituted benzocycloheptapyridine, substituted or unsubstituted carbazol, substituted or unsubstituted tetrahydrocarbazols, substituted or unsubstituted dibenzocycloheptenes, substituted or unsubstituted benzoimidazoles, substituted or unsubstituted piperazines, substituted or unsubstituted benzamides, substituted or unsubstituted benzhydrol, and substituted or unsubstituted diazabenzoazulene, substituted or unsubstituted oxobenzimidazole, 3,4 pyrrolo-dihydroquinoline, carbamoyl-2,3,4,9-tetrahydro-cabazol, and pharmaceutically acceptable salts thereof. In accordance with a preferred embodiment of the present invention, n is 2. In a more preferred embodiment of the present invention, n is 2 and m is from 0 to 3.
In accordance with another embodiment of the present invention, compounds have the formula
where R1 and R2 are independently hydrogen, alkyl having from 1 to about 7 carbon atoms, aryl, aralkyl, and cycloalkyl having from about 3 to about 6 carbon, X is oxygen, nitrogen or carbon, and m is from 0 to about 3.
Another type of compound in accordance with the present invention has the formula
where R3 is a group having the formula
where V is carbon or nitrogen, R6 is hydrogen, alkyl, aryl or aralkyl, R7 is hydrogen, alkyl, aralkyl, cycloalkyl, alkylcycloalkyl, alkylsulfonylcycloalkyl, alkylsulfonylaryl, alkylsulfonylaminoalkyl or alkylsulfonylalkyl and R8 is hydrogen, carbonyl or a direct bond.
Preferred compounds in accordance with this embodiment of the present invention include those where R3 has the formula
In accordance with the present invention, R7 is preferably selected form the group consisting of:
In yet another embodiment of the present invention, the compounds have the formula
where R3 is a group having the formula
where R9 and R11 are hydrogen, alkyl, aryl, alkylaryl, cycloalkyl or together form a cyoalkyl or cycloheteroalkyl group, and R10 is hydrogen, alkyl or a carboxylic acid group, and R12 and R13 are independently hydrogen, halogen, alkyl, alkoxy or amino.
In a preferred embodiment of the present invention the compounds have the formula
In another embodiment of the present invention the compounds have the formula
where V is carbon or nitrogen, W is carbon, nitrogen or oxygen, U is carbon or nitrogen, B is a single or double bond, and R14 and R15 are independently hydrogen, halogen, or alkyl.
where V is carbon or nitrogen, W is carbon, nitrogen or oxygen, U is carbon or nitrogen, B is a single or double bond, and R15 and R16 are independently hydrogen, halogen or alkyl.
In still another embodiment of the present invention, the compounds have the formula
where R6 is hydrogen, alkyl, alkylaryl or aralkyl, and R7 is hydrogen, alkyl, aralkyl, cycloalkyl, alkylcycloalkyl, alkylsulfonylcycloalkyl, alkylsulfonylaryl, alkylsulfonylaminoalkyl or alkylsulfonylalkyl.
Another type includes those containing short linear aliphatic chains depending from a nitrogen atom such as those found with imipramine.
In accordance with this aspect of the present invention, R1 and R2 are independently hydrogen, alkyl having from 1 to about 7 carbon atoms including but not limited to methyl, ethyl, propyl, butyl, isobutyl, and pentyl, aryl including but not limited to phenyl and pyridinyl, aralkyl such as benzyl, and cycloalkyl having from about 3 to about 6 carbon atoms including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl, A is a lower alkyl, lower heteroalkyl, carbonyl or cycloalkyl, X is 0 or 1, R1 and R2 are independently hydrogen, alkyl having from 1 to about 7 carbon atoms, aryl, aralkyl, and cycloalkyl having from about 3 to about 6 carbon atoms, R20 is hydrogen, phenyl or lower alkyl, and R21 is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylaryoxy, substituted or unsubstituted indole, substituted or unsubstituted phenothiazine, substituted or unsubstituted dibenzoxazepine, substituted or unsubstituted dibenzathiazepine, substituted or unsubstituted oxopthalazine, substituted or unsubstituted quinoline, substituted or unsubstituted dihydroquinoline, substituted or unsubstituted dibenzodiazepine, substituted or unsubstituted benzocycloheptapyridine, substituted or unsubstituted carbazol, substituted or unsubstituted tetrahydrocarbazols, substituted or unsubstituted dibenzocycloheptenes, substituted or unsubstituted benzoimidazoles, substituted or unsubstituted piperazines, substituted or unsubstituted benzamides, substituted or unsubstituted benzhydrol, and substituted or unsubstituted diazabenzoazulene, substituted or unsubstituted oxobenzimidazole, 3,4 pyrrolo-dihydroquinoline, carbamoyl-2,3,4,9-tetrahydro-cabazol, and pharmaceutically acceptable salts thereof.
In accordance with another embodiment of the present invention, the compounds have the formula
where A is a lower alkyl, lower heteroalkyl or cycloalkyl, R20 is hydrogen, phenyl or lower alkyl and R21 is a group having the formula
where V is carbon or nitrogen, W is carbon, nitrogen or oxygen, U is carbon or nitrogen, R23 and R24 are independently hydrogen, halogen, alkyl or alkoxy, and B is a single or double bond.
In accordance with another aspect of the present invention, the compounds have the formula
where A is a lower alkyl, lower heteroalkyl or cycloalkyl, R20 is hydrogen, phenyl or lower alkyl and R21 is a group having the formula
where V is carbon or nitrogen, W is carbon, nitrogen or oxygen, U is carbon or nitrogen, R23 and R24 are independently hydrogen, halogen, alkyl or alkoxy, and B is a single or double bond.
In accordance with another embodiment of the present invention, the compounds have the formula
where A is a lower alkyl, lower heteroalkyl or cycloalkyl, R20 is hydrogen, phenyl or lower alkyl and R21 is a group having the formula
where V is carbon or nitrogen, U is carbon or nitrogen, R23 and R24 are independently hydrogen, halogen, alkyl or alkoxy, and B is a single or double bond.
In accordance with another embodiment of the present invention, the compounds have the formula
where A is a lower alkyl, lower heteroalkyl or cycloalkyl, R20 is hydrogen, phenyl or lower alkyl and R21 is a group having the formula
where V is carbon or nitrogen, R6 is hydrogen, alkyl, aryl or aralkyl, and R7 is hydrogen, halogen, aralkyl, cycloalkyl, alkylcycloalkyl, alkylsulfonylcycloalkyl, alkylsulfonylaryl, alkylsulfonylaminoalkyl or alkylsulfonylalkyl.
In accordance with another embodiment of the present invention, the compounds have the formula
where A is a lower alkyl, lower heteroalkyl or cycloalkyl, R20 is hydrogen, phenyl or lower alkyl, R26 is hydrogen, alkyl, alkoxy, alkylaryl, alkenylaryl, halogen, halogen-substituted alkyl, alkylaryloxy, alkanoyl, arylalkanoyl, or a group having the formula
where R27 R28 and R29 are independently substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl, and R25 is hydrogen, hydroxy, alkyl, alkylaryl, aryl, cycloalkyl or heteroaryl.
In accordance with another embodiment of the present invention, the compounds have the formula
where R31, R32, R33, R34 are independently hydrogen, halogen, alkyl, alkoxy or a group having the formula (CH2)nCOOH where n=1 to about 5.
Unless otherwise specifically identified or claimed for preferred embodiments, the following general definitions are used in accordance with the present invention.
“Alkyl” refers to a branched or straight chain acyclic alkyl group comprising one to about ten carbon atoms, a haloalkyl group, an alkenyl group, an alkynyl group, a bridged cycloalkyl group, a cycloalkyl group or a heterocyclic ring.
“Lower alkyl” refers to a branched or straight chain acyclic alkyl group comprising one to about six carbon atoms. In accordance with the present invention, lower alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, pentyl, neopentyl, iso-amyl, hexyl, and the like.
“Haloalkyl” refers to a lower alkyl group, an alkenyl group, an alkynyl group, a bridged cycloalkyl group, a cycloalkyl group or a heterocyclic ring, to which is appended one or more halogens, as defined herein. Exemplary haloalkyl groups include trifluoromethyl, chloromethyl, 2-bromobutyl, 1-bromo-2-chloro-pentyl, and the like.
“Alkenyl” refers to a branched or straight chain C2-C10 hydrocarbon which can comprise one or more carbon-carbon double bonds. In accordance with the present invention, alkenyl groups include propylenyl, buten-1-yl, isobutenyl, penten-1-yl, 2,2-methylbuten-1-yl, 3-methylbuten-1-yl, hexan-1-yl, hepten-1-yl, octen-1-yl, and the like.
“Alkynyl” refers to an unsaturated acyclic C2-C10 hydrocarbon which can comprise one or more carbon-carbon triple bonds. In accordance with the present invention, alkynyl groups include ethynyl, propynyl, butyn-1-yl, butyn-2-yl, pentyl-1-yl, pentyl-2-yl, 3-methylbutyn-1-yl, hexyl-1-yl, hexyl-2-yl, hexyl-3-yl, 3,3-dimethyl-butyn-1-yl, and the like.
“Cycloalkyl” refers to a saturated or unsaturated cyclic hydrocarbon comprising from about 3 to about 8 carbon atoms. Cycloalkyl groups can be unsubstituted or substituted with one, two or three substituents independently selected from alkyl, alkoxy, amino, alkylamino, dialkylamino, arylamino, diarylamino, alkylarylamino, aryl, amidyl, ester, hydroxy, halo, carboxyl, alkylcarboxylic acid, alkylcarboxylic ester, carboxamido, alkylcarboxamido, oxo and nitro. In accordance with the present invention, cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl and the like.
“Heterocyclic ring or group” refers to a saturated, unsaturated, cyclic or aromatic or polycyclic hydrocarbon group having about 3 to about 7 carbon atoms where 1 to about 4 carbon atoms are replaced by one or more nitrogen, oxygen and/or sulfur atoms. Sulfur maybe in the thio, sulfinyl or sulfonyl oxidation state. The heterocyclic ring or group can be fused to an aromatic hydrocarbon group. Heterocyclic groups can be unsubstituted or substituted with one, two or three substituents independently selected from alkyl, alkoxy, amino, alkylamino, dialkylamino, arylamino, diarylamino, alkylarylamino, hydroxy, oxo, thial, halo, carboxyl, carboxylic ester, alkylcarboxylic acid, alkylcarboxylic ester, aryl, arylcarboxylic acid, arylcarboxylic ester, amidyl, ester, carboxamido, alkylcarboxamido, arylcarboxamido, sulfonic acid, sulfonic ester, sulfonamido and nitro. In accordance with the present invention, heterocyclic groups include pyrrolyl, 3-pyrrolinyl,4,5,6-trihydro-2H-pyranyl, pyridinyl, 1,4-dihydropyridinyl, pyrazolyl, triazolyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, imidazolyl, indolyl, thiophenyl, furanyl, tetrhydrofuranyl, tetrazolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolindinyl, oxazolindinyl 1,3-dioxolanyl, 2,6-dioxabicydo[3,3,0]octanyl, 2-imidazonlinyl, imidazolindinyl, 2-pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, 2H-pyranyl, 4H-pyranyl, piperidinyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, pyrazinyl, piperazinyl, 1,3,5-triazinyl, 1,3,5-trithianyl, benzo(b)thiophenyl, benzimidazolyl, quinolinyl, and the like. “Heterocyclic compounds” refer to mono- and polycyclic compounds comprising at least one aryl or heterocyclic ring.
“Aryl” refers to a monocyclic, bicyclic, carbocyclic or heterocyclic ring system comprising one or two aromatic rings. In accordance with the present invention, aryl groups include phenyl, pyridyl, napthyl, quinoyl, tetrahydronaphthyl, furanyl, indanyl, indenyl, indoyl, and the like. Aryl groups (including bicylic aryl groups) can be unsubstituted or substituted with one, two or three substituents independently selected from alkyl, alkoxy, amino, alkylamino, dialkylamino, arylamino, diarylamino, alkylarylamino, hydroxy, carboxyl, carboxylic ester, alkylcarboxylic acid, alkylcarboxylic ester, aryl, arylcarboxylic acid, arylcarboxylic ester, alkylcarbonyl, arylcarbonyl, amidyl, ester, carboxamido, alkylcarboxamido, carbomyl, sulfonic acid, sulfonic ester, sulfonamido and nitro. In accordance with the present invention, substituted aryl groups include tetrafluoro-phenyl, pentafluorophenyl, sulfonamide, alkylsulfonyl, arylsulfonyl, and the like.
“Alkylaryl” refers to an alkyl group to which is appended an aryl group. In accordance with the present invention, alkylaryl groups include benzyl, phenylethyl, hydroxybenzyl, fluorobenzyl, fluorophenylethyl, and the like.
“Arylalkyl” refers to an aryl radical, attached to an alkyl radical in accordance with the present invention,
“Cycloalkylalkyl” refers to a cycloalkyl radical attached to an alkyl radical in accordance with the present invention,
“Alkoxy” refers to RO-, wherein R is an alkyl group in accordance with the present invention. In accordance with the present invention, alkoxy groups include methoxy, ethoxy, t-butoxy, cyclopentyloxy, and the like.
“Arylalkoxy or alkoxyaryl” refers to an alkoxy group, as defined herein, to which is appended an aryl group in accordance with the present invention, In accordance with the present invention, arylalkoxy groups indude benzyloxy, phenylethoxy, chlorophenylethoxy, and the like.
“Alkoxyaryl” refers to an alkoxy group, in accordance with the present invention, appended to an alkyl group. In accordance with the present invention, alkoxyaryl groups include methoxymethyl, methoxyethyl, isopropoxymethyl, and the like.
In accordance with the present invention, R1 is hydrogen, an alkyl having from 1 to about 5 carbon atoms including but not limited to methyl, ethyl, propyl, butyl, isopropyl, isobutyl, and pentyl, an aryl including but not limited to phenyl, aralkyl such as benzyl, or cycloalkyl having from about 3 to about 6 carbon atoms including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In accordance with a preferred embodiment of the present invention R2 is hydrogen, lower alkyl including but not limited to methoxy and ethoxy. In accordance with a more preferred embodiment of the present invention, R2 is hydrogen or OCH3.
In accordance with a preferred embodiment of the present invention R1 and R2 are independently hydrogen, methyl, ethyl, propyl or phenyl. In accordance with a more preferred embodiment of the present invention, R1 is methyl, ethyl or phenyl and R2 is hydrogen. In accordance with a most preferred embodiment of the present invention, R1 and R2 are both ethyl.
Illustrative compounds in accordance with a most preferred embodiment of the present invention include the following:
The compounds of the present invention can be administered alone but will generally be administered in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example, the compounds of the present invention can be administered orally, in the form of tablets, capsules, multi-particulates, elixirs, solutions or suspensions, which may contain flavoring or coloring agents, either for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications. Suitable formulations of the compounds of the present invention may be in coated or uncoated form, as desired.
Such solid pharmaceutical compositions, for example, tablets, may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate, glycine and starch (preferably corn, potato or tapioca starch), disintegrants such as sodium starch glycollate, and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, may be included.
Desipramine hydrochloride (1 equivalent, 0.5 gram) was added drop wise to a stirred solution of potassium carbonate (2 equivalents, 0.456 gram) in dry DMF at 0° C. Diethylchlorophosphate (1.2 equivalents, 0.33 ml) which had been dissolved in dry DMF was added drop wise to this mixture and stirred for 12 hours at room temperature. The reaction mixture was quenched with water, extracted with ethyl acetate, the organic layer separated, washed with brine solution and dried over anhydrous sodium sulfate. The dried material was concentrated and purified by column chromatography to provide a pale yellow liquid (yield: 0.33 gram) and analyzed by HPLC (purity 93.1%). The FTIR, MS and 1H NMR spectra were consistent with the assigned with the empirical formula of C22H31N2O3P.
Desipramine hydrochloride (1 equivalent, 0.3 gram) was added drop wise to a stirred solution of potassium carbonate (2 equivalents, 0.27 gram) in dry DMF at 0° C. Methyl chloroform (1.2 equivalents, 0.1 ml) which had been dissolved in dry DMF was added drop wise to this mixture and stirred for 6 hours at room temperature. The reaction mixture was quenched with water, extracted with ethyl acetate, the organic layer separated, washed with brine solution and dried over anhydrous sodium sulfate. The dried material was concentrated and purified by column chromatography to provide a pale yellow liquid (yield: 0.18 gram) and analyzed by HPLC (purity 97.7%). The FTIR, MS and 1H NMR spectra were consistent with the assigned with the empirical formula of C20H24N2O2.
Desipramine hydrochloride (1 equivalent, 0.2 gram) was added drop wise to a stirred solution of potassium carbonate (5 equivalents, 0.45 gram) in dry DMF at 0° C. Propyl chloroform (1.5 equivalents, 0.1 ml) which had been dissolved in dry DMF was added drop wise to this mixture and stirred for 6 hours at room temperature. The reaction mixture was quenched with water, extracted with ethyl acetate, the organic layer separated, washed with brine solution and dried over anhydrous sodium sulfate. The dried material was concentrated and purified by column chromatography to provide a yellow liquid (yield: 0.12 gram) and by HPLC (purity 95.7%). The FTIR, MS and 1H NMR spectra were consistent with the assigned structure with the empirical formula of C22H28N2O2.
Desipramine hydrochloride (1 equivalent, 0.3 gram) was added drop wise to a stirred solution of potassium carbonate (5 equivalents, 0.68 gram) in dry DMF at 0° C. Isobutyl chloroform (1.5 equivalents, 0.18 ml) which had been dissolved in dry DMF was added drop wise to this mixture and stirred for 6 hours at room temperature. The reaction mixture was quenched with water, extracted with ethyl acetate, the organic layer separated, washed with brine solution and dried over anhydrous sodium sulfate. The dried material was concentrated and purified by column chromatography to provide a pale yellow liquid (yield: 0.18 gram) and analyzed by HPLC (purity 96.4%) The FTIR, MS and 1H NMR spectra were consistent with the assigned structure with the empirical formula of C22H28N2O2.
Desipramine hydrochloride (1 equivalent, 0.3 gram) was added drop wise to a stirred solution of potassium carbonate (2.5 equivalents, 0.34 gram) in dry DMF at 0° C. Octyl chloroform (1.5 equivalents, 0.429 grams) which had been dissolved in dry DMF was added drop wise to this mixture and stirred for 12 hours at room temperature. The reaction mixture was quenched with water, extracted with ethyl acetate, the organic layer separated, washed with brine solution and dried over anhydrous sodium sulfate. The dried material was concentrated and purified by column chromatography to provide a pale yellow liquid (yield: 0.12 gram) and analyzed by HPLC (purity 95.3%) The FTIR, MS and 1H NMR spectra were consistent with the assigned structure with the empirical formula of C27H38N2O2.
In the following tables, including Tables 1 and 2 and the tables given in the discussion of Examples 6 through 11, RIC-02 corresponds to the compound of Example 1 (Compound Number E1413), RIC-5a corresponds to the compound of Example 2 (Compound Number E1414), RIC-5b corresponds to the compound of Example 3 (Compound Number E 1415), RIC-5c corresponds to the compound of Example 4 (E1416), RIC-5d corresponds to the compound of Example 5 (E1417).
Pooled human plasma was obtained from Bioreclamation (East Meadow, N.Y.) by collection into sodium EDTA as the anticoagulant, and was stored at ca −20° C. prior to use. Prior to use, the plasma defrosted and was spun at ca. 3000 rpm for 5 minutes to remove any precipitate. The pH of the plasma was adjusted to pH 7.4 by careful addition of NaH2PO4 buffer.
Plasma stability was assessed by incubation of 10 μM of each compound prepared in Examples 1-5 with human plasma, in duplicate, at ca. 37° C. with shaking. Each compound prepared in Examples 1-5 was also incubated at 10 μM in PBS as a control for compound heat stability. Aliquots were removed at 0, 0.5, 1 and 2 hours and stored at −20° C. until analysis.
For analysis, plasma samples were extracted in 1 part acetonitrile and isolation of the supernatant. Analysis of each compound prepared in Examples 1-5 in plasma extracts was conducted by an LC-MS method at each time interval and quantification was achieved by comparison of the response due to the sample to that of a three point standard curve. Appearance of the parent drug the hydroxymetabolites were also monitored at each time interval. The % degradation following incubation at each time point was calculated by comparison of the parent concentration to that at 0 minutes.
The results of the stability testing in human plasma are shown in the following table:
Sprague-Dawley rat plasma was obtained by collection into sodium EDTA as the anticoagulant, and was stored at ca −20° C. prior to use. Prior to use, the plasma defrosted and was spun at ca. 3000 rpm for 5 minutes to remove any precipitate. The pH of the plasma was adjusted to pH 7.4 by careful addition of NaH2PO4 buffer.
Plasma stability was assessed by incubation of 10 μM of each compound prepared in Examples 1-5 with rat plasma, in duplicate, at ca. 37° C. with shaking. Each compound prepared in Examples 1-5 was also incubated at 10 μM in PBS as a control for compound heat stability. Aliquots were removed at 0, 0.5, 1 and 2 hours and stored at −20° C. until analysis.
For analysis, plasma samples were extracted in 1 part acetonitrile and isolation of the supernatant. Analysis of each compound prepared in Examples 1-5 in plasma extracts was conducted by an LC-MS method at each time interval and quantification was achieved by comparison of the response due to the sample to that of a three point standard curve. Appearance of the parent drug and the hydroxymetabolites were also monitored at each time interval. The % degradation following incubation at each time point was calculated by comparison of the parent concentration to that at 0 minutes.
The results of the stability testing in rat plasma are shown in the following table:
The stability of each compound prepared in Examples 1-5 was assessed in both simulated gastric fluids and intestinal fluids alone and intestinal fluids spiked with alkaline phosphatase to approximate the enzymatic activity of the intestinal wall.
The stability of each compound prepared in Examples 1-5 was assessed in duplicate by incubation of 10 μM of each compound at ca. 37° C. and shaking with each of the following: simulated gastric fluids (saline pH approximately 1, plus pepsin); simulated intestinal fluids (phosphate pH 6 with pepsin); and alkaline phosphatase enhanced simulated intestinal fluids (phosphate pH 6 with pepsin and ± alkaline phosphatase). Aliquots were removed at 0, 0.5, 1 and 2 hours, extracted with one volume of organic solvent and stored at −20° C. until analysis.
Analysis of each compound prepared in Examples XXXX in gastric fluid and intestinal fluid extracts was conducted by an LC-MS method at each time interval and quantification was achieved by comparison of the response due to the sample to that of a three point standard curve. Appearance of the parent drug and the hydroxymetabolites were also monitored at each time interval. The % degradation following incubation at each time point was calculated by comparison of the parent concentration to that at 0 minutes.
The results of the stability testing in simulated gastric fluids are shown in the following table:
The results of the stability testing in simulated intestinal fluids are shown in the following table:
The metabolic stability of each compound prepared in Examples 1-5 was assessed in microsomal preparations obtained from BD Gentest (Woburn, Mass.).
The metabolic stability of each compound prepared in Examples 1-5 was assessed in duplicate by incubation of 10 μM compound with 0.5 mg/mL microsomal protein, 1 mM in 0.1 M phosphate buffer, pH 7.4 in the presence and absence of a CYP3A4 inhibitor (ketoconazole). The reaction mixture was pre-incubated, in the absence of the microsomes, at ca. 37° C. for 5 minutes, followed by initiation of the incubation by the addition of microsomal protein and maintained at ca. 37° C. for a further 0, 30 and 60 minutes. After the appropriate incubation time, the mixtures were quenched by the addition of one volume of acetonitrile and the supernatant was isolated by centrifugation. Positive control incubations (7-ethoxycoumarin) were performed in the same manner as the compounds from Examples 1-5 and quenched after 0 and 30 minutes. In addition, negative control incubations were performed for 60 minutes in the absence of NADPH to assess chemical stability.
Analysis of supernatants from each time interval was conducted for each compound prepared in Examples 1-5 by LC-MS analysis. Quantification of the disappearance on the parent drug was achieved by comparison of the sample response to that of a suitable standard curve constructed in 0.1 M phosphate buffer, pH 7.4. The standard curve ranged between ≦1% up to ≧100% of the dosing concentration.
The % turnover following 60 minutes of incubation was calculated by comparison of the parent concentration to that at 0 minutes. The % degradation was calculated in the same manner from the negative control incubations. Appearance of the parent drug and the hydroxymetabolites were also monitored at each time interval.
The results of the metabolic testing in microsomes without inhibitor are shown in the following table:
The results of the metabolic testing in microsomes with ketoconazole inhibitor are shown in the following table:
The metabolic stability of each compound prepared in Examples 1-5 was assessed in the presence of CYP2D6 and CYP3A4 obtained from BD Gentest (Woburn, Mass.).
The metabolic stability of each compound prepared in Examples 1-5 was assessed in duplicate by incubation of 10 μm compound with recombinant human CYP2D6 and 3A4 using similar conditions to those in Example 9. Samples were removed for analysis at 0, 30 and 60 minutes and extracted with one volume of organic solvent. Appropriate controls were included. Quantification of the disappearance of the prodrug was conducted LC-MS. Appearance of metabolites was also monitored.
The results of the metabolic testing in the presence of CYP3A4 isozyme are shown in the following table:
The results of the metabolic testing in the presence of CYP2D6 isozyme are shown in the following table:
The metabolic stability of each compound prepared in Examples 1-5 was assessed in human hepatocytes obtained from In Vitro Technologies (Baltimore, Md.).
The metabolic stability of each compound prepared in Examples 1-5 was assessed in duplicate by incubation of 10 μM compound with human hepatocytes after thawing of cryopreserved suspensions. The hepatocytes were maintained in Modified Williams' E medium (HMM, Clonetics, MD) supplemented with 0.1 μM dexamethasone, 0.1 μM insulin and 0.05 % gentamicin immediately after thawing.
Each compound prepared in Examples 1-5 was tested by incubation in duplicate with the hepatocyte suspensions (1.0×106 viable cells/mL HHM media) and incubated for 0, 1, 2 and 4 hours at 37° C. at 5% CO2. Incubations were terminated by the addition of two volumes of ice-cold methanol, cell debris was removed by centrifugation and the supernatant was stored at approximately −70° C. prior to analysis.
Negative and positive control incubations were performed in duplicate under the same conditions as described for the prodrugs. Negative control incubations: An incubation of each compound prepared in Examples 1-5 in Modified Williams' E media (HHM media), in the absence of hepatocytes was performed alongside the hepatocyte incubations. Positive control incubations: Incubations with a positive control (7-ethoxycoumarin; 100 μM) was performed with hepatocytes from each species for 1 hour alongside the prodrug incubations. Analysis of metabolic turnover was performed by HPLC. Quantification of the parent compound was achieved by comparison of the sample response to that of a suitable standard curve. The standard curve ranged between ≦1% up to ≧100% of the dosing concentration. The % turnover following 1, 2 and 4 hours of incubation was calculated by comparison of the parent concentration to that at 0 minutes.
The present invention has been described in specific detail and with particular reference to its preferred embodiments; however, it will be obvious to those having skill in the art that modifications and changes can be made thereto without departing from the spirit and scope of the invention.
This patent application claims the benefit of prior filed copending provisional application Nos. 60/600,699 filed Aug. 11, 2004, and 60/673,545 filed Apr. 21, 2005 each titled Noncardiotoxic Pharmaceutical Compositions, which are hereby incorporated by reference in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2832786 | Tilford et al. | Apr 1958 | A |
| 2994638 | Malz et al. | Aug 1961 | A |
| 3058879 | Malz et al. | Oct 1962 | A |
| 3188309 | Mukaiyama et al. | Jun 1965 | A |
| 4126442 | Shen et al. | Nov 1978 | A |
| 4493931 | Chekroun et al. | Jan 1985 | A |
| 4584132 | Albrecht et al. | Apr 1986 | A |
| 5070082 | Murdock et al. | Dec 1991 | A |
| 5077283 | Murdock et al. | Dec 1991 | A |
| 5116827 | Murdock et al. | May 1992 | A |
| 5212291 | Murdock et al. | May 1993 | A |
| 5334741 | Quin et al. | Aug 1994 | A |
| 5387748 | Demuth et al. | Feb 1995 | A |
| 5512570 | Dorn et al. | Apr 1996 | A |
| 5631256 | Demuth et al. | May 1997 | A |
| 5646163 | Demuth et al. | Jul 1997 | A |
| 5672600 | Demuth et al. | Sep 1997 | A |
| 5688955 | Kruse et al. | Nov 1997 | A |
| 5691336 | Dorn et al. | Nov 1997 | A |
| 5807846 | Roark et al. | Sep 1998 | A |
| 5958905 | Chan et al. | Sep 1999 | A |
| 6521605 | Arnold et al. | Feb 2003 | B1 |
| 6593374 | Pinney et al. | Jul 2003 | B2 |
| 6746794 | Mandal et al. | Jun 2004 | B2 |
| 6956054 | Pero et al. | Oct 2005 | B2 |
| 7001926 | Pinney et al. | Feb 2006 | B2 |
| Number | Date | Country |
|---|---|---|
| 0 671 389 | Sep 1995 | EP |
| 2006099 | Apr 1999 | ES |
| 1786037 | May 1991 | SU |
| WO 9902531 | Jan 1999 | WO |
| WO 2006026395 | Sep 2006 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20060035863 A1 | Feb 2006 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60600699 | Aug 2004 | US | |
| 60673545 | Apr 2005 | US |
